CINCINNATI–(BUSINESS WIRE)–Eikonoklastes Therapeutics, a biotech company advancing novel immunotherapies to treat cancers and other diseases, announces today the appointment of Tom Finn, retired president of P&G Global Personal Health Care, and former president of P&G Pharmaceuticals, to its Board of Directors.

I am delighted to once again work at the cutting edge of healthcare technology development

“We are thrilled to welcome Tom to our board during a promising time for Eikonoklastes,” said Bruce Halpryn PhD, chief executive officer of Eikonoklastes Therapeutics. “Tom is a recognized leader in the biopharmaceutical industry as well as in the healthcare industry more broadly. His extensive corporate strategy experience will be instrumental as we develop innovative medicines to treat people with cancer and several other diseases with significant unmet clinical need.”

Finn recently retired following a decorated career at The Procter & Gamble Co., most recently as President of Global Personal Health Care. Prior to this role, Finn held executive management roles at P&G, including President of Global Personal Health Care & Global Pharmaceuticals, VP of NA Pharmaceuticals, Global Strategic Planning, and New Business Development, VP of Worldwide Strategic Planning and New Business Development, and GM of Pharmaceuticals. Finn serves as a board member of the Cincinnati Children’s Hospital Medical Center. Finn received his BA in Economics from Hamilton College.

“I am delighted to once again work at the cutting edge of healthcare technology development,” said Tom Finn. “The Eikonoklastes technology is very promising and has the potential to offer tremendous advances in the treatment of multiple diseases with significant unmet need, beginning with Triple Negative Breast Cancer. I look forward to joining the Board of this exciting venture, offering my 36 years of health care leadership experience to serve the Eikonoklastes management team and stakeholders.”


Eikonoklastes Therapeutics is advancing a new generation of tissue factor (TF) immunotherapies for the treatment of Triple Negative Breast Cancer and a broad range of other cancers and diseases with high morbidity and high unmet clinical needs. Eikonoklastes Therapeutics was founded and is led by a management team with longstanding experience of successful drug development. The lead compound ET-101 is a state-of-the-art immune conjugate developed in the lab of Zhiwei Hu MD, PhD, at The Ohio State University. The company closed an oversubscribed seed financing in Q2 2020 led by CincyTech (

More at:



Samuel Lee MD MBA MPH, Chief Business Officer